Fludarabine, cytarabine, G‐CSF and idarubicin (FLAG‐IDA) for the treatment of poor‐risk myelodysplastic syndromes and acute myeloid leukaemia

E. Parker, Jane; Pagliuca, Antonio; Mijović, Aleksandar; Cullis, Jonathan; Czepulkowski, Barbara; Rassam, Sal; Samaratunga, I.; Grace, R.; Gover, Pamela; J Mufti, G

doi:10.1046/j.1365-2141.1997.4763281.x

Public

Fludarabine, cytarabine, G‐CSF and idarubicin (FLAG‐IDA) for the treatment of poor‐risk myelodysplastic syndromes and acute myeloid leukaemia

Published in British Journal of Haematology • Dec 1, 1997

Authors:

Jane E. Parker

Antonio Pagliuca

Aleksandar Mijović

Abstract

Nineteen patients with high-risk myelodysplastic syndrome (MDS)/acute myeloid leukaemia (AML) received fludarabine, cytarabine, granulocyte-colony stimulating factor (G-CSF), and idarubicin chemotherapy (de novo MDS/MDS-AML, nine; relapsed/refractory MDS/AML, seven; therapy-related MDS, three). Medi...

Subject

Idarubicin

Fludarabine

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!